Webinar 3 Emerging Strategies in the Management of BED The Role for Pharmacologic and Non-Pharmacologic Approaches

BED Webinars
1 CDR 1 AMA PRA Category 1 Credit(s)
Launch Date:
April 30, 2015
Expiration Date:
The accreditation for this activity has expired.

Primary Audience:

General Medicine and Family Physicians and Dietitians who care for patients with binge eating disorder. Other health care providers, including nurse practitioners and physician assistants, may also participate.

Relevant Terms:

Binge Eating Disorder, Eating Disorders, Obesity

Paul E. Keck, Jr., MD

Paul E. Keck, Jr., MD
President and CEO, Lindner Center of HOPE
Professor of Psychiatry and Neuroscience
Executive Vice Chairman, Department of Psychiatry
University of Cincinnati College of Medicine
Cincinnati, Ohio

Paul E. Keck, Jr., MD, is Craig and Frances Lindner Professor of Psychiatry and Behavioral Neuroscience at the University of Cincinnati (UC) College of Medicine. He is also President-CEO of the Lindner Center of HOPE, a state-of-the-science, UC-affiliated comprehensive mental health center in Mason, Ohio. Dr. Keck has conducted extensive research in bipolar disorder and clinical psychopharmacology, supported by grants from the NIMH, NARSAD, the Stanley Foundation, and industry. Since 1996, he has been in the top 10 of the most cited scientists in the world publishing in the fields of psychology and psychiatry.
A magna cum laude and Phi Beta Kappa graduate of Dartmouth College, Dr. Keck received his MD with honors from the Mount Sinai School of Medicine, New York, NY.  He served his internship in Internal Medicine at the Beth Israel Medical Center in New York and completed his residency training in Psychiatry at Harvard Medical School and McLean Hospital, Belmont, MA.  Dr. Keck remained on faculty at McLean and Harvard before joining the Department of Psychiatry at the University of Cincinnati in 1991. 
Dr. Keck is the author of over 375 scientific papers in leading medical journals.  He has also contributed over 170 reviews and chapters to major psychiatric textbooks, and is the editor or author of 6 scientific books.
Dr. Keck is the recipient of numerous honors, including the Gerald Klerman Young Investigator Award from the National Depressive and Manic-Depressive Association (NDMDA); the Gerald Klerman Senior Investigator Award from the Depression & Bipolar Support Alliance (DBSA); the Exemplary Psychiatrist Award from the National Alliance of the Mentally Ill (NAMI); the Philip Isenberg Teaching Award from Harvard Medical School; the Nancy C A Roeske Certificate for medical student education from the American Psychiatric Association; Distinguished Fellow of the American Psychiatric Association; the Wyeth-Ayerst AADPRT Mentorship Award; two Communicator Awards for Continuing Medical Education; the Outstanding Physician Partner Award of the Postgraduate Institute for Medicine; and two Golden Apple Teaching Awards from the University of Cincinnati College of Medicine. He is listed as one of the Best Doctors in Cincinnati by Cincinnati Magazine; The Best Doctors in America, a directory of the top one percent of physicians in the United States as rated by their peers; and is listed among The World’s Most Influential Scientific Minds by ScienceWatch.
1. Describe the prevalence, burden, and public health impact of BED
2. Identify misconceptions, biases, and negative attitudes commonly associated with BED in order to assess how they impact diagnosis, treatment, and communication with your at-risk patients
3. Review and assess non-pharmacologic approaches to managing BED
4. Compare and contrast pharmacologic approaches to treating BED

This educational activity is supported by an independent educational grant from Shire Pharmaceuticals.

According to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relevant relationships with any commercial interests related to this activity. The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation. All educational materials are reviewed for fair balance, scientific objectivity and levels of evidence. Disclosures are as follows:

Paul E. Keck, Jr., MD
Nature of Relationship
Commercial Entity
Advisory Board/Consultant:
Self: Alkermes, Actavis (Forest Laboratories), Merck, Otsuka, ProPhase, Shire Pharmaceuticals, Supernus, Sunovion
Spouse: Shire, Sunovion
Grant Recipient/Research Support
(Funds paid to Lindner Center of HOPE)
Spouse (PI): Actavis (Forest Laboratories), Alkermes, AstraZeneca,  GlaxoSmithKline; Lilly; Marriott Foundation; NIMH; Orexigen; Pfizer; Shire Pharmaceuticals, Takeda Pharmaceuticals, Teva Pharmaceutical Industries, Ltd. (Cephalon)
Intellectual Property Patients
Self (co-inventor): Methods of treating obsessive-compulsive spectrum disorder comprises the step of administering an effective amount of tramadol to an individual - no financial gain from this patent; Spouse (inventor) Use of sulfamate derivatives for treating impulse control disorders - has received payments from Johnson & Johnson Pharmaceutical Research & Development which has exclusive rights under patent.
Independent Clinical Reviewers
Maria C. La Via, MD, Associate Professor of Psychiatry, Medical Director of the Eating Disorders Program, University of North Carolina, Chapel Hill, North Carolina; Shareholder: Pfizer (self and spouse).
Christy Maloney, RD, LD/LDN, CPT, Nutritional Therapist, The Renfrew Center: No relevant financial relationships with any commercial interests.
Angela Sims, MPH, RD, LDN, Consultant Dietitian, Genesis Healthcare: No relevant financial relationships with any commercial interests.

John J.D. Juchniewicz, MCIS, CCMEP, American Academy of CME and Deborah Dean, Michelle Yechout, Jillian Lokere, PhD, and Wendy Gloffke, PhD (editorial assistance provided), peerXchange: No relevant financial relationships with any commercial interests.
This activity will review off-label or investigational information.
Antidepressants (SSRIs; SNRIs; TCAs; NRIs; NDRIs); Anti-obesity agents (orlistat; sibutramine and fenfluramine (both withdrawn from the market); and Antieplielptics (phenytoin, valproate, carbamazepine, lamotrigine, zonisamide, and topiramate)
This activity is designed for use by health care professionals for educational purposes only. The opinions expressed in this educational activity are those of the faculty, and do not represent those of the Academy or peerXchange. Continuing Professional Education Provider Accreditation does not constitute endorsement by CDR of a provider, program, or materials.

This activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically, and draw conclusions only after careful consideration of all available scientific information.

Accreditation and Credit Designation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of American Academy of CME, Inc., (Academy) and peerXchange. The American Academy of CME, Inc., is accredited by the ACCME to provide continuing medical education for physicians.
Live Credit Statement
The American Academy of CME, Inc., designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Live Event: May 19, 2015; 7PM (EDT)
Archive Credit Statement
The American Academy of CME, Inc., designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Release date:  April 30, 2015
Expiration date:  April 30, 2016
American Academy of CME, Inc, (AM311) is a Continuing Professional Education  (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR). Registered dietitians (RD) will receive 1.0 continuing professional education units (CPEUs) for completion of this program. 
Suggested CDR Learning Codes: 4170, 4180, 5320, 5370

Method of Participation & How to Claim Credit
There are no fees to participate in the activity.  After reviewing the CME/CE information including the learning objectives and disclosure statements, learners will complete a brief, 15-minute self-study module. The self-study module provides foundational knowledge which will enable learners to more fully engage the webinar content. Learners will then either participate in the live webinar or view a recording of the event. To receive CME/CE credit for your participation, you will need to complete the activity pre-test, post-test (achieving a passing grade of 70% or greater) and program evaluation at the conclusion of the webinar. Dietitian learners may also submit evaluations of the quality of activities/materials on the CDR website.

For more information about the American Academy of CME privacy policy, please access http://www.academycme.org/privacy.htm
For any questions, please contact: CEServices@academycme.org
© 2015. This CME/CE-certified activity is held as copyrighted © by American Academy of CME, Inc. and peerXchange. Through this notice, the Academy and peerXchange grant permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).

Supported Browsers:
Internet Explorer 8.0+ for Windows 2000, 2003, Vista, XP, Windows 7, Windows 8    
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6+ for Mac OSX 10.7 and above

For video playback, install the latest version of Flash or Quicktime.